We have characterized the molecular changes underlying the transformation of a JAK2V617F +-myelofibrosis with trisomy 8, into a JAK2V617F-negative leukemia. Leukemic clone did not carry JAK2V617F mutation, but showed ASXL1 mutation (R693X). This mutation was identified in a low percentage at diagnosis by next-generation sequencing. Using this technology in serial specimens during the follow-up, we observed a progressive expansion of the ASXL1-mutated minor clone, whereas the JAK2V617F +-clone carrying trisomy 8 decreased. Hematologic progression occurred simultaneously with an ASXL1-R693X-negative lung-cancer. This is the first report showing a clear association between the expansion of an ASXL1-mutated clone and the leukemic transformation of myelofibrosis. © 2013 Ferrer-Marín et al.; licensee BioMed Central Ltd.
CITATION STYLE
Ferrer-Marín, F., Bellosillo, B., Martínez-Avilés, L., Soler, G., Carbonell, P., Luengo-Gil, G., … Vicente, V. (2013). Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: Clonal evolution and hierarchy revealed by next-generation sequencing. Journal of Hematology and Oncology, 6(1). https://doi.org/10.1186/1756-8722-6-68
Mendeley helps you to discover research relevant for your work.